Holen Sie sich die Stockscreener-App
1.54
9.22%
0.13
Handel nachbörslich:
1.51
-0.03
-1.95%
Schlusskurs vom Vortag:
$1.41
Offen:
$1.4
24-Stunden-Volumen:
320.03K
Relative Volume:
1.12
Marktkapitalisierung:
$6.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-18.65M
KGV:
-0.2482
EPS:
-6.205
Netto-Cashflow:
$-16.66M
1W Leistung:
+10.00%
1M Leistung:
-75.35%
6M Leistung:
-82.89%
1J Leistung:
-91.95%
1-Tages-Spanne:
$1.33
$1.605
1-Wochen-Bereich:
$1.275
$1.605
52-Wochen-Spanne:
$1.03
$30.60
Fibrobiologics Inc Stock (FBLG) Company Profile
Firmenname
Fibrobiologics Inc
Sektor
Branche
Telefon
281-671-5150
Adresse
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.54 | 6.40M | 0 | -18.65M | -16.66M | -6.205 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-24 | Eingeleitet | Maxim Group | Buy |
Fibrobiologics Inc Aktie (FBLG) Neueste Nachrichten
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Market Outlook: Does FibroBiologics Inc have a competitive edge2026 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity - Bitget
FibroBiologics presents preclinical data on thymic organoids By Investing.com - Investing.com India
FibroBiologics presents preclinical data on thymic organoids - Investing.com
Injectable thymus organoids restored diverse T cells in mouse studies - Stock Titan
FibroBiologics ends Webster sublease early, updates principal office address - Investing.com UK
FibroBiologics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing - Minichart
FibroBiologics, Inc. Files 8-K/A Amendment to Update Executive Office Address and Correct Item Disclosure – April 2026 7817 - Minichart
Fibrobiologics IncEnters Lease Termination Agreement With United Fire & Casualty On April 3, 2026SEC Filing - TradingView — Track All Markets
FibroBiologics ends Webster sublease early, updates principal office address By Investing.com - Investing.com South Africa
FibroBiologics (NASDAQ: FBLG) exits Webster lease early, eyeing $0.8M savings - Stock Titan
FibroBiologics Ends Texas Sublease, Consolidates Houston Operations - TipRanks
[SCHEDULE 13G] FibroBiologics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
FibroBiologics (NASDAQ: FBLG) ends sublease to save $0.8M rent - Stock Titan
Analyst Downgrade: Is FibroBiologics Inc subject to activist investor interest2026 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Aug Patterns: Is FibroBiologics Inc subject to activist investor interest2026 Levels & Fast Moving Trade Plans - baoquankhu1.vn
Price to sales ratio of FibroBiologics, Inc. – FWB:SG00 - TradingView — Track All Markets
Price to sales ratio of FibroBiologics, Inc. – LSX:A426UV - TradingView
FibroBiologics, Inc. Financial Statements – LSX:A426UV - TradingView — Track All Markets
Aug Ideas: Is FibroBiologics Inc benefiting from interest rate changes2026 Stock Rankings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Market Review: Is FibroBiologics Inc benefiting from interest rate changes2026 Snapshot & Low Drawdown Trading Techniques - baoquankhu1.vn
FibroBiologics, Inc. Announces Reverse Stock Split and Certificate Amendment – SEC Form 8-K Filing Summary - Minichart
FibroBiologics Implements One-for-Twenty Reverse Stock Split - TipRanks
FibroBiologics (NASDAQ: FBLG) completes 1:20 reverse stock split - Stock Titan
FibroBiologics closes $3M public offering with warrants By Investing.com - Investing.com Canada
FibroBiologics Announces Closing of $3 Million Public Offering - Sahm
Fibrobiologics announces closing of $3 million public offering - marketscreener.com
Fibrobiologics Announces Closing Of $3 Million Public Offering - TradingView — Track All Markets
FibroBiologics Closes $3M Public Offering - National Today
FibroBiologics Announces Public Offering and Warrant Agreements - TipRanks
FibroBiologics Raises $2.5 Million Net in Public Offering Priced at $1.32, Adds Warrants Upside - TradingView — Track All Markets
FibroBiologics closes $3M public offering with warrants - Investing.com
FibroBiologics (NASDAQ: FBLG) closes $3M stock and warrant offering - Stock Titan
FibroBiologics, Inc. Common Stock (FBLG) Stock Price Today & Analysis - Gotrade
FibroBiologics (NASDAQ: FBLG) sells shares and warrants; reverse split in place - Stock Titan
FibroBiologics, Inc. Announces Pricing of Public Offering for 2.27 Million Shares and Warrants - Moomoo
FBLG: Advancing Fibroblast Therapy on Multiple Fronts - Yahoo Finance
FibroBiologics manufactures first batch of CYWC628 drug product for trials - TipRanks
FibroBiologics prices $3M public offering at $1.32/share By Investing.com - Investing.com Australia
FibroBiologics completes first CYWC628 batch for clinical trials By Investing.com - Investing.com South Africa
FibroBiologics prices $3M public offering at $1.32/share - Investing.com
FibroBiologics Announces Pricing of $3 Million Public Offering - The Manila Times
After a $3M raise, FibroBiologics targets working capital needs - Stock Titan
FibroBiologics Completes Manufacturing of Diabetic Foot Ulcer Drug - National Today
Finanzdaten der Fibrobiologics Inc-Aktie (FBLG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):